Funding round
eGenesis Series C
eGenesis, which works in xenotransplantation solutions development in Cambridge, raised $125M in a Series C round announced on 2 Mar 2021, led by Samsara BioCapital. 18 firms took part. It is eGenesis' third venture round on record; the one before was a Series B in Nov 2019.
$125M
Amount raised
Not disclosed
Post-money valuation
18
Investors
1 lead
Valuation
What this round says about the price
eGenesis did not disclose a valuation in this round. It came 16 months after eGenesis' Series B. It is 28% of the $454M eGenesis has raised in the venture rounds on record. eGenesis raised again 42 months later: a Series D round of $191M in Sep 2024.
eGenesis' funding rounds
eGenesis has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Samsara BioCapital led the round with 17 other firms.
Lead investor
- Samsara BioCapital new investor
Also in the round
- backs 15 venture-backed companies new investor
- backs 98 venture-backed companies new investor
- backs 25 venture-backed companies new investor
- Invus backs 83 venture-backed companies new investor
- backs 11 venture-backed companies new investor
- backs 7 venture-backed companies new investor
- backs 57 venture-backed companies new investor
- backs 14 venture-backed companies new investor
- backs 4 venture-backed companies new investor
- Monashee Investment Management new investor
- Osage University Partners new investor
- Leaps by Bayer new investor
- Fresenius Medical Care Ventures new investor
- ARCH Venture Partners backs 99 venture-backed companies new investor
- backs 37 venture-backed companies new investor
- Khosla Ventures backs 396 venture-backed companies new investor
- backs 18 venture-backed companies new investor
Joined the board: Isaac Ciechanover (Polaris Partners) and Mark Pruzanski (Intercept Pharmaceuticals).
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
43 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $85M, and this round was 1.5 times the median. The closest in time, other companies' Series C rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| insitro Biotechnology | 15 Mar 2021 | $400M | not disclosed | Canada Pension Plan Investment Board |
| Biotechnology | 24 Mar 2021 | $82M | not disclosed | aMoon and Northpond Ventures |
| Biotechnology | 31 Mar 2021 | $41M | not disclosed | Magnetar Capital |
| Biotechnology | 23 Mar 2021 | $35M | not disclosed | Paragon Biosciences |
| Biotechnology | 18 Feb 2021 | $95M | not disclosed | Redmile Group |
| Biotechnology | 22 Feb 2021 | $93M | not disclosed | HSG and LYFE Capital |
| Biotechnology | 2 Apr 2021 | $75M | $563M | 8VC and Founders Fund |
| Biotechnology | 26 May 2021 | $200M | not disclosed | Cormorant Asset Management and HBM Healthcare Investments |
Sources
Where this comes from
Reported by 10 sources.
Questions
Frequently asked
How much did eGenesis raise in its Series C round?
eGenesis raised $125M in its Series C round, announced in Mar 2021.
Who led eGenesis' Series C round?
Samsara BioCapital led it, with Farallon, Polaris Partners, HBM Healthcare Investments, Invus and LifeSci Venture Partners and 12 more.
What was eGenesis' valuation at the Series C round?
It was not disclosed.
How does it compare with other Series C rounds in Biotechnology?
43 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $85M, and this round was 1.5 times the median.
Did eGenesis raise again after this round?
Yes: a Series D round in Sep 2024 of $191M.